Admission to Trading

Summary by AI BETAClose X

Dr. Martens plc has announced the admission of 623,983 further ordinary shares to trading on the London Stock Exchange's Main Market, bringing the total number of shares in issue to 967,943,542. These shares, fully fungible with existing ordinary shares, were admitted between January 20, 2026, and May 31, 2026, under a block admission related to the company's employee share schemes.

Disclaimer*

Dr. Martens PLC
05 June 2026
 

5 June 2026

Dr. Martens plc ("the Company")

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with PRM 1.6.4R.

1

Details of the issuer

a)

Name

Dr. Martens plc

b)

LEI

213800QPT8YM6NQZPH28

2

Details of the transferable securities admitted to trading

a)

Name, type and identification code

Ordinary shares of GBP 0.01

ISIN: GB00BL6NGV24

b)

Regulated market

London Stock Exchange - Main Market (XLON)

c)

Number of further securities issued and admitted

623,983

d)

Total number of securities in issue following admission

967,943,542

e)

Fungibility

Fully fungible with existing Ordinary Shares

3

Admission details

a)

Date(s) of admission

20 January 2026 to 31 May 2026 (admitted under a block admission dated 12 December 2024 in connection with the Company's employee share schemes)

b)

Prospectus information

N/A

 

For further information, please contact:
Paul Rolling, Head of Secretariat
+447584243562

 

ENDS


About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques.

A brand built to put a bounce in the step of those who stand out from the crowd, Dr. Martens is available through Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels. The brand's collections range from its Original silhouettes - The Icons such as the 1460 boot, 1461 shoe, 2976 Chelsea boot, and Adrian loafer - to modern franchises like the Zebzag, Buzz, and Lowell. The lineup also includes an extensive range of sandals, a dedicated Kids collection, and a curated selection of bags, small leather goods, and accessories.

Every Dr. Martens product reflects craftsmanship, heritage, timeless style, comfort, and versatility. Having transcended generations, the brand stays as relevant today as it was at its inception. Its signature yellow welt stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops remain iconic symbols recognised around the world.

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index.

For more information, visit www.drmartens.com  or www.drmartensplc.com  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Dr. Martens (DOCS)
UK 100

Latest directors dealings